Advances in Drug Resistance Research

Christudas Morais, PhD (Editor)
Centre for Kidney Disease Research, School of Medicine,The University of Queensland, Translational Research Institute, Queensland, Australia

Series: Public Health in the 21st Century
BISAC: MED058170



Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick


Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:



Drug resistance continues to be a major problem in the effective treatment of many diseases. Resistance to chemotherapy, whether intrinsic or extrinsic, is the result of at least three well defined mechanisms: prevention of the interaction of drug with the target, decreased intracellular concentration of the drug due to an increased efflux or a decreased influx, and enzymatic modification or destruction of the drug. With the advancement in technology, the molecular mechanisms of drug resistance have been unravelling at a rapid rate.

This book is a timely review of such advances in drug resistance research. The nine chapters of this book, written by a group of clinicians and scientists, elegantly summarises recent advances in our understanding of this important clinical problem with emphasis on cisplatin, fibroblasts, natural compounds, erythropoiesis-stimulating agents, prostate cancer and kidney cancer. This book will be an important contribution to science, and an invaluable tool for researchers who are interested in drug resistance. (Imprint: Nova Biomedical )


Chapter 1. Mechanisms of Cisplatin Resistance: DNA Repair and Cellular Implications
(Mark N. Adams, Nicholas W. Ashton, Nicolas Paquet, Ken O’Byrne and Derek J. Richard, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia and others)
Free Download Available

Chapter 2. Multi-Drug Resistance in Cancer and New Approaches for its Overcoming
(Jelena Dinic, Tijana Stankovic, Jasna Bankovic and Milica Pešic, Institute for Biological Research “Siniša Stankovic”, University of Belgrade, Belgrade, Serbia)

Chapter 3. Tumor Fibroblasts: Pivotal Players in Drug Resistance
(Ivy Chung, University of Malaya Cancer Research Institute, Department of Pharmacology, Faculty of Medicine, University of Malaya)
Free Download Available

Chapter 4. Erythropoiesis Stimulating Agent Resistance
(Stacey O’Shea, Sunil V. Badve and David W. Johnson, Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia and others)

Chapter 5. Therapeutic Options for Metastatic Castration Resistant Prostate Cancer: Has the Situation Improved?
(Varinder Jeet, Australian Prostate Cancer Research Centre, Queensland Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Australia)

Chapter 6. Current Trends in Prostate Cancer Treatment and Drug Resistance
(Raja S. Vasireddy and Colleen C. Nelson, Australian Prostate Cancer Research Centre, Queensland Brisbane, Queensland, Australia and others)

Chapter 7. Resistance of Metastatic Renal Cell Carcinomas to Chemo and Immunotherapy: Clinicians’ Perspective
(Ng Keng Lim and Simon T. Wood, Department of Surgery, University Malaya, Kuala Lumpur, Malaysia and others)

Chapter 8. Resistance of Renal Cell Carcinoma to Targeted Therapy
(Retnagowri Rajandram, Teng Ai Ong and Marniza Saad, Department of Surgery, University of Malaya, Kuala Lumpur, Malaysia and others)
Free Download Available

Chapter 9. Molecular Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma
(Turibius Simon, Glenda C. Gobe, Chung-Shu Wu, Fu-Hsiang Ko and Christudas Morais, Department of Materials Science and Engineering, and Institute of Nanotechnology, National Chiao Tung University, Hsinchu, Taiwan and others)


You have not viewed any product yet.